ECSP14020640A - Inhibidores de la beta-secretasa - Google Patents

Inhibidores de la beta-secretasa

Info

Publication number
ECSP14020640A
ECSP14020640A ECIEPI201420640A ECPI201420640A ECSP14020640A EC SP14020640 A ECSP14020640 A EC SP14020640A EC IEPI201420640 A ECIEPI201420640 A EC IEPI201420640A EC PI201420640 A ECPI201420640 A EC PI201420640A EC SP14020640 A ECSP14020640 A EC SP14020640A
Authority
EC
Ecuador
Prior art keywords
beta
secretase inhibitors
disorders
secretase
inhibitors
Prior art date
Application number
ECIEPI201420640A
Other languages
English (en)
Spanish (es)
Inventor
Zhenrong Xu
Suresh Singh
Lanqi Jia
Yajun Zheng
Deepak Lala
Klaus Fuchs
Yuri Bukhtiyarov
Jonathan Reeves
Yi Zhao
Cornelia Dorner-Ciossek
Salvacion Cacatian
Jing Yuan
Georg Rast
Shankar Venkatraman
Lawrence Wayne Dillard
Angel Morales-Ramos
Original Assignee
Sanofi Aventis Deutschiand Gmbh
Vitae Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschiand Gmbh, Vitae Pharmaceuticals Inc filed Critical Sanofi Aventis Deutschiand Gmbh
Publication of ECSP14020640A publication Critical patent/ECSP14020640A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/50Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/45Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/47Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02Sulfinic acids; Derivatives thereof
    • C07C313/06Sulfinamides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C331/00Derivatives of thiocyanic acid or of isothiocyanic acid
    • C07C331/02Thiocyanates
    • C07C331/14Thiocyanates having sulfur atoms of thiocyanate groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/687Unsaturated compounds containing a keto groups being part of a ring containing halogen
    • C07C49/697Unsaturated compounds containing a keto groups being part of a ring containing halogen containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/703Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
    • C07C49/747Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/753Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
    • C07C49/755Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00Systems containing at least three condensed rings
    • C07C2603/93Spiro compounds
    • C07C2603/94Spiro compounds containing "free" spiro atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ECIEPI201420640A 2012-03-05 2014-09-29 Inhibidores de la beta-secretasa ECSP14020640A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261606786P 2012-03-05 2012-03-05

Publications (1)

Publication Number Publication Date
ECSP14020640A true ECSP14020640A (es) 2015-06-30

Family

ID=47902355

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201420640A ECSP14020640A (es) 2012-03-05 2014-09-29 Inhibidores de la beta-secretasa

Country Status (40)

Country Link
US (4) US8981112B2 (enExample)
EP (1) EP2822930B1 (enExample)
JP (1) JP6161643B2 (enExample)
KR (1) KR20140138774A (enExample)
CN (1) CN104271558B (enExample)
AP (1) AP4029A (enExample)
AR (1) AR090241A1 (enExample)
AU (2) AU2013230523B2 (enExample)
BR (1) BR112014021269A2 (enExample)
CA (1) CA2864143C (enExample)
CL (1) CL2014002334A1 (enExample)
CO (1) CO7091177A2 (enExample)
CY (1) CY1117543T1 (enExample)
DK (1) DK2822930T3 (enExample)
EA (1) EA024995B1 (enExample)
EC (1) ECSP14020640A (enExample)
ES (1) ES2568928T3 (enExample)
GE (1) GEP20176799B (enExample)
HR (1) HRP20160415T1 (enExample)
HU (1) HUE027289T2 (enExample)
IL (1) IL233887A (enExample)
IN (1) IN2014DN06710A (enExample)
MA (1) MA35945B1 (enExample)
ME (1) ME02390B (enExample)
MX (1) MX353432B (enExample)
MY (1) MY171091A (enExample)
NZ (1) NZ629239A (enExample)
PE (1) PE20141972A1 (enExample)
PH (1) PH12014501963A1 (enExample)
PL (1) PL2822930T3 (enExample)
RS (1) RS54730B1 (enExample)
SG (1) SG11201404600VA (enExample)
SI (1) SI2822930T1 (enExample)
SM (1) SMT201600114B (enExample)
TN (1) TN2014000326A1 (enExample)
TW (1) TWI557112B (enExample)
UA (1) UA113641C2 (enExample)
UY (1) UY34654A (enExample)
WO (1) WO2013134085A1 (enExample)
ZA (1) ZA201405846B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE031902T2 (en) 2008-05-23 2017-08-28 Siwa Corp Procedures and Preparations to Promote Regeneration
UY32490A (es) 2009-03-13 2010-10-29 Boehringer Ingelheim Int Inhibidores de beta-secretasa
CN102812005B (zh) 2010-02-24 2014-12-10 生命医药公司 β-分泌酶抑制剂
TWI557112B (zh) * 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 β-分泌酶抑制劑
JP6030752B2 (ja) 2012-05-09 2016-11-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング オキセタン−3−イルメタンアミンの製造方法
TW201422592A (zh) * 2012-08-27 2014-06-16 Boehringer Ingelheim Int β-分泌酶抑制劑
US9290477B2 (en) 2012-09-28 2016-03-22 Vitae Pharmaceuticals, Inc. Inhibitors of β-secretase
JP6288588B2 (ja) 2012-11-21 2018-03-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング N−スルフィニル−α−アミノアミドの製造方法
CA2961603C (en) 2014-09-19 2021-07-13 Siwa Corporation Anti-age antibodies for treating inflammation and auto-immune disorders
UY36347A (es) 2014-10-07 2016-04-01 Astrazeneca Ab Compuestos y su uso como inhibidores de bace
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
DK3677598T3 (da) 2016-02-19 2022-05-30 Siwa Corp Fremgangsmåde og sammensætning til behandling af cancer, drab på metastatiske cancerceller og forebyggelse af cancermetastaser under anvendelse af antistof mod avancerede glykeringsslutprodukter (age)
US11958900B2 (en) 2016-04-15 2024-04-16 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
JP2019518763A (ja) 2016-06-23 2019-07-04 シワ コーポレーション 様々な疾患及び障害の治療において使用するためのワクチン
EP3510029B1 (en) * 2016-09-07 2025-11-05 The Regents of The University of California Allosteric corticotropin-releasing factor receptor 1 (crfr1) antagonists that decrease p-tau and improve cognition
CA3059803A1 (en) 2017-04-13 2018-10-18 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
WO2020198583A1 (en) 2019-03-27 2020-10-01 Insilico Medicine Ip Limited Bicyclic jak inhibitors and uses thereof
US12297244B2 (en) 2019-06-05 2025-05-13 Rensselaer Polytechnic Institute Systems and methods for inhibiting γ-secretase production of amyloid-β peptides
BE1027699B1 (fr) * 2021-01-28 2022-04-01 Trasis S A Procédé de purification de macro-agrégats de sérumalbumine humaine radiomarqués
CN113082209A (zh) * 2021-03-31 2021-07-09 中国科学技术大学 Cd4+t细胞源性bace1、ep2、ep4作为阿尔茨海默病治疗靶点的应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5745185A (en) 1980-07-21 1982-03-13 Eisai Co Ltd Hydantoin derivative and its preparation
AU655666B2 (en) 1991-08-28 1995-01-05 Pharmacia & Upjohn Company Spirocyclic benzopyran imidazolines
AU691296B2 (en) 1994-05-06 1998-05-14 Pharmacopeia Drug Discovery, Inc. Combinatorial dihydrobenzopyran library
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
JP5020638B2 (ja) 2003-12-15 2012-09-05 シェーリング コーポレイション 複素環式アスパルチルプロテアーゼインヒビター
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
EP1758907B1 (en) 2004-06-16 2009-02-18 Wyeth Diphenylimidazopyrimidine and -imidazole amines as inhibitors of b-secretase
WO2006009653A1 (en) 2004-06-16 2006-01-26 Wyeth Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase
EP1804794B1 (en) 2004-10-13 2013-07-31 Merck Sharp & Dohme Corp. Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer s disease
MX2007016182A (es) 2005-06-14 2008-03-07 Schering Corp Inhibidores de aspartil proteasas.
JP2008543840A (ja) 2005-06-14 2008-12-04 シェーリング コーポレイション アスパルチルプロテアーゼインヒビター
TW200738683A (en) 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
AU2006266167A1 (en) 2005-06-30 2007-01-11 Wyeth Amino-5-(6-membered)heteroarylimidazolone compounds and the use thereof for beta-secretase modulation
EP1913193B1 (en) 2005-07-29 2018-12-05 Koninklijke Philips N.V. Steam ironing devive for generating a burst of steam
TW200730523A (en) 2005-07-29 2007-08-16 Wyeth Corp Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
CA2623245A1 (en) 2005-09-26 2007-04-05 Wyeth Amino-5- [4- (difluoromethoxy) phenyl] -5-phenylimidazolone compounds as inhibitors of the beta-secretase (bace)
EP1942105B8 (en) 2005-10-25 2014-08-13 Shionogi&Co., Ltd. Aminodihydrothiazine derivative
US7872009B2 (en) 2005-11-21 2011-01-18 Amgen Inc. Beta-Secretase modulators and methods of use
DE102005057688A1 (de) 2005-12-01 2007-06-14 Endress + Hauser Flowtec Ag Vorrichtung zur Bestimmung und/oder Überwachung des Massedurchflusses eines gasförmigen Mediums
WO2007078813A2 (en) 2005-12-19 2007-07-12 Wyeth 2-AMINO-5-PIPERIDINYLIMIDAZOLONE COMPOUNDS AND USE THEREOF FOR β-SECRETASE MODULATION
EP1974278A4 (en) 2005-12-20 2012-01-04 Fieldbus Foundation SYSTEM AND METHOD FOR IMPLEMENTING INSTRUMENTED SAFETY SYSTEMS
WO2007100536A1 (en) 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
WO2007146225A2 (en) 2006-06-12 2007-12-21 Schering Corporation Heterocyclic aspartyl protease inhibitors
CA2657106C (en) 2006-07-18 2011-09-20 Astellas Pharma Inc. Aminoindane derivative or salt thereof
EP2063889A4 (en) 2006-09-07 2009-09-16 Merck & Co Inc SPIROPIPERIDINE BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
WO2008076044A1 (en) 2006-12-20 2008-06-26 Astrazeneca Ab Novel 2-amino-5, 5-diaryl-imidazol-4-ones
TW200831484A (en) 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
TW200831091A (en) 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
PE20090160A1 (es) 2007-03-20 2009-02-11 Wyeth Corp COMPUESTOS AMINO-5-[4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5-FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA
CL2008000791A1 (es) 2007-03-23 2008-05-30 Wyeth Corp Compuestos derivados de 2-amino-5-(4-difluorometoxi-fenil)-5-fenil-imidazolidin-4-ona; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la actividad bace excesiva, tales como enferm
ES2476605T3 (es) 2007-04-24 2014-07-15 Shionogi & Co., Ltd. Derivados de aminohidrotiazina sustituidos con grupos cíclicos
WO2008133273A1 (ja) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. アルツハイマー症治療用医薬組成物
TW200902503A (en) 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
EP2077637B1 (en) 2007-12-12 2020-03-11 Alcatel Lucent System and method for protecting payload information in radio transmission
BRPI0907563A2 (pt) 2008-02-18 2015-08-04 Hoffmann La Roche Derivados de 4,5-di-hidro-xazol-2-il amina
TWI431004B (zh) 2008-05-02 2014-03-21 Lilly Co Eli Bace抑制劑
WO2010013302A1 (ja) 2008-07-28 2010-02-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 スピロアミノジヒドロチアジン誘導体
US8501733B2 (en) 2008-07-28 2013-08-06 Eisai R&D Management Co., Ltd. Spiroaminodihydrothiazine derivatives
US8450308B2 (en) 2008-08-19 2013-05-28 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
US8426447B2 (en) 2008-09-11 2013-04-23 Amgen Inc. Spiro-tricyclic ring compounds as beta-secretase modulators and methods of use
EA201170722A1 (ru) 2008-11-23 2011-10-31 Пфайзер Инк. Лактамы в качестве ингибиторов бета-секретазы
UY32490A (es) 2009-03-13 2010-10-29 Boehringer Ingelheim Int Inhibidores de beta-secretasa
WO2011072064A1 (en) 2009-12-08 2011-06-16 Array Biopharma Inc. S piro [chroman - 4, 4 ' - imidazol] ones as beta - secretase inhibitors
CN102812005B (zh) * 2010-02-24 2014-12-10 生命医药公司 β-分泌酶抑制剂
AR080865A1 (es) 2010-03-31 2012-05-16 Array Biopharma Inc Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer.
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
TWI557112B (zh) 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 β-分泌酶抑制劑

Also Published As

Publication number Publication date
US9949975B2 (en) 2018-04-24
AU2013230523B2 (en) 2017-10-05
AR090241A1 (es) 2014-10-29
MA35945B1 (fr) 2014-12-01
CO7091177A2 (es) 2014-10-21
AU2013230523A1 (en) 2014-09-18
IL233887A0 (en) 2014-09-30
MY171091A (en) 2019-09-25
CA2864143A1 (en) 2013-09-12
WO2013134085A1 (en) 2013-09-12
JP2015511958A (ja) 2015-04-23
NZ629239A (en) 2016-04-29
BR112014021269A2 (pt) 2017-07-04
HRP20160415T1 (hr) 2016-06-03
TN2014000326A1 (en) 2015-12-21
EP2822930A1 (en) 2015-01-14
KR20140138774A (ko) 2014-12-04
EA201491534A1 (ru) 2014-12-30
US8981112B2 (en) 2015-03-17
CN104271558A (zh) 2015-01-07
PE20141972A1 (es) 2014-12-28
CL2014002334A1 (es) 2015-04-17
EA024995B1 (ru) 2016-11-30
US20180344734A1 (en) 2018-12-06
TWI557112B (zh) 2016-11-11
IL233887A (en) 2017-09-28
ES2568928T3 (es) 2016-05-05
SG11201404600VA (en) 2014-10-30
ZA201405846B (en) 2017-08-30
US20150150872A1 (en) 2015-06-04
US20170196867A1 (en) 2017-07-13
PL2822930T3 (pl) 2016-09-30
WO2013134085A8 (en) 2014-09-04
SI2822930T1 (sl) 2016-09-30
CY1117543T1 (el) 2017-04-26
CN104271558B (zh) 2016-08-24
AP2014007900A0 (en) 2014-08-31
US20130289050A1 (en) 2013-10-31
UA113641C2 (xx) 2017-02-27
CA2864143C (en) 2020-04-14
PH12014501963B1 (en) 2014-11-17
JP6161643B2 (ja) 2017-07-12
EP2822930B1 (en) 2016-01-20
AU2017236042B2 (en) 2019-01-03
HK1205739A1 (zh) 2015-12-24
TW201339139A (zh) 2013-10-01
ME02390B (me) 2016-09-20
HUE027289T2 (en) 2016-09-28
RS54730B1 (sr) 2016-10-31
DK2822930T3 (en) 2016-04-25
IN2014DN06710A (enExample) 2015-05-22
MX353432B (es) 2018-01-11
MX2014010625A (es) 2015-04-08
GEP20176799B (en) 2018-01-10
PH12014501963A1 (en) 2014-11-17
AP4029A (en) 2017-02-05
AU2017236042A1 (en) 2017-10-26
SMT201600114B (it) 2016-08-31
UY34654A (es) 2013-09-30
US9526727B2 (en) 2016-12-27

Similar Documents

Publication Publication Date Title
ECSP14020640A (es) Inhibidores de la beta-secretasa
CL2018002794A1 (es) Compuestos bicíclicos
CO2018000648A2 (es) Compuestos de piridina sustituidos, intermediarios para su preparación y composiciones que los comprenden
GT201400034A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
GT201400162A (es) Composición y método para el diagnóstico y el tratamiento de las enfermedades asociadas a la degeneración de las neuritas
GT201300209A (es) Compuestos y composiciones como inhibidores de la trk
MX2015003140A (es) Formulaciones de enzalutamida.
UY35023A (es) Derivados c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso
NI201300080A (es) Formas sólidas de 3 - ( 5 - amino - 2 - metil - 4 - oxo - 4h - quinazolin - 3 - il ) - piperidin - 2, 6 - diona, y sus composiciones farmacéuticas y usos
CL2015002222A1 (es) Compuestos de azabencimidazol como inhibidores de isoenzimas pde4 para el tratamiento del snc y otros trastornos.
ECSP20021132A (es) Enantiómeros de tiazoles sustituidos compuestos antivirales
UY34991A (es) Inhibidores de la beta-secretasa
UY34725A (es) Nuevos derivados de tienopirimidina, procesos para su preparación y sus usos terapéuticos.
MX386250B (es) Formulaciones novedosas.
ECSP14032516A (es) N-[4-(quinolin-4-iloxi)ciclohexil(metil)](hetero)aril-carboxamidas como antagonistas del receptor de andrógenos, su producción y usos como productos medicinales
GT201500124A (es) Forma sòlida de un derivado de dihidro-pirido-oxazina
WO2014052398A8 (en) Inhibitors of beta-secretase
UY34703A (es) Ciclobutilcarboxamidas, proceso para su preparación, composiciones pesticidas y composiciones farmacéuticas que las comprenden, y usos de las mismas como nematicidas
ES2421810R1 (es) Intermedios utiles para la sintesis de fexofenadina, procedimientos para su preparacion y para la preparacion de fexofenadina